NOVO NORDISK A/S 
By General Meeting, at which the following were adopted:
Financial year 2013 and 2014 The Company's audited Annual Report 2013.
The remuneration of the Board of Directors for 2013 and the level for 2014.
Distribution of profit according to the adopted Annual Report 2013. The dividend will be DKK 4.50 per A and B share of DKK 0.20.
Elections Re-election of Göran Ando as chairman and Jeppe Christiansen as vice chairman of the Board of Directors.
Re-election of Bruno Angelici, Liz Hewitt, Thomas Paul Koestler and Hannu
Ryöppönen as members of the Board of Directors.
Election of Helge Lund as new member of the Board of Directors.
Re-election of PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab
as the Company's auditor.
Shares and capital Reduction of the Company's B share capital by cancellation of part of the Company's own holding of B shares. The Company's B shares are reduced by DKK 20,000,000 from DKK 442,512,800 to DKK 422,512,800.
Authorisation to the Board of Directors until the next Annual General Meeting to allow the Company to repurchase own shares of up to 10% of the share capital subject to a holding limit of 10% of the share capital.
Other Donation to the World Diabetes Foundation (WDF) of an amount up to a total of DKK 654 million to be granted from the financial year 2015 through to the financial year 2024.
Amendments to the Articles of Association allowing Annual Reports, General
Meetings and related documents to be in English.
Approval of revised Remuneration Principles.
Proposals from a shareholder were not adopted.
Novo Nordisk A/SInvestor Relations
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
Company announcement No 17 / 2014
Page 2 of 2
Composition of the Board of Directors and its committees
In February 2014, Novo Nordisk employees in Denmark elected four board members for a period of four years: Liselotte Hyveled, Anne Marie Kverneland, Søren Thuesen Pedersen and Stig Strøbæk.
After the Annual General Meeting, the Board of Directors held a board meeting to appoint members of the Audit Committee and the Nomination Committee. The Board of
Directors, including its committees are now composed as follows:
Göran Ando (chairman and chairman of the Nomination Committee)
Jeppe Christiansen (vice chairman)
Bruno Angelici (member of the Nomination Committee)
Liz Hewitt (member of the Audit Committee and the Nomination Committee)
Liselotte Hyveled (employee representative)
Thomas Paul Koestler
Anne Marie Kverneland (employee representative)
Helge Lund (member of the Audit Committee)
Søren Thuesen Pedersen (employee representative and member of the
Nomination Committee)
Hannu Ryöppönen (chairman of the Audit Committee)
Stig Strøbæk (employee representative and member of the Audit Committee)
Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 38,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B
shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock
Exchange (NVO). For more information, visit novonordisk.com.
Further informationMedia:
Mike Rulis +45 4442 3573 mike@novonordisk.com
Ken Inchausti (US) +1 609 514 8316 kiau@novonordisk.com
Investors:
Kasper Roseeuw Poulsen +45 4442 4303 krop@novonordisk.com
Frank Daniel Mersebach
Daniel Bohsen
+45 4442 0604
+45 3079 6376
fdni@novonordisk.com dabo@novonordisk.com
Lars Borup Jacobsen +45 3075 3479 lbpj@novonordisk.com
Jannick Lindegaard (US) +1 609 786 4575 jlis@novonordisk.com
Investor Relations
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
Company announcement No 17 / 2014
|
distributed by
|
